Jazz Pharmaceuticals PLC (JAZZ) Holdings Boosted by Credit Suisse AG
Credit Suisse AG grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.4% in the third quarter, Holdings Channel reports. The fund owned 93,239 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,158 shares during the period. Credit Suisse AG’s holdings in Jazz Pharmaceuticals were worth $15,675,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. BlackRock Inc. raised its stake in shares of Jazz Pharmaceuticals by 64.0% in the second quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock worth $753,311,000 after acquiring an additional 1,706,417 shares during the last quarter. FMR LLC raised its stake in shares of Jazz Pharmaceuticals by 12.1% in the second quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock worth $1,143,203,000 after acquiring an additional 715,595 shares during the last quarter. AGF Investments Inc. bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $78,345,000. Voya Investment Management LLC bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $70,215,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Jazz Pharmaceuticals by 14.0% in the third quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock worth $284,205,000 after acquiring an additional 207,954 shares during the last quarter. 91.53% of the stock is owned by institutional investors.
In other Jazz Pharmaceuticals news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $165.20, for a total value of $33,040.00. Following the completion of the sale, the executive vice president now owns 25,372 shares of the company’s stock, valued at $4,191,454.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Seamus Mulligan bought 50,000 shares of the stock in a transaction on Thursday, November 15th. The stock was purchased at an average cost of $144.56 per share, with a total value of $7,228,000.00. The disclosure for this purchase can be found here. Insiders sold 6,600 shares of company stock valued at $1,063,472 in the last ninety days. Insiders own 3.90% of the company’s stock.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business had revenue of $469.37 million during the quarter, compared to the consensus estimate of $482.64 million. During the same period in the previous year, the firm posted $3.22 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 14.0% compared to the same quarter last year. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.6 earnings per share for the current fiscal year.
A number of equities analysts have weighed in on JAZZ shares. B. Riley dropped their target price on shares of Jazz Pharmaceuticals from $219.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, November 8th. BMO Capital Markets boosted their price target on shares of Jazz Pharmaceuticals from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 8th. Mizuho reissued a “neutral” rating and set a $173.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, October 15th. ValuEngine downgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, November 7th. Finally, Cowen set a $200.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $189.76.
TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-holdings-boosted-by-credit-suisse-ag/2663992.html.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
See Also: What is a Futures Contract?
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.